Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

PRICED: Avantor 8NC3 sr notes USD1.55bn 4.625% at 100; EUR400m 3.875% at 100

HYC US Market: Deal Flow - GeneralHYC European Market: Deal Flow - General

Avantor Funding Inc (AVTR) approx USD2bn (up from USD1.452bn) 144A/Reg S sr notes 2-part. B3/B-/BB (positive/positive/stable). Via GS/Citi/Barc/JPM/BofA joint books, PNC, HSBC, Evercore (US$ tranche only), Jefferies as co-managers. No reg rights. Settles 07/17 (T+8).

   - USD1.550bn (up from USD1bn) due 07/15/28 (8y). NC3 (MWC T+50bp), then at 102.313, 101.156, 100. Equity claw: 3y 40% at 104.625. 144A CUSIP: 05352TAA7. IPT: 5.00%-5.25%. Px talk: 4.75%-5.00%. Launched: $1.55bn at 4.625%. Priced: 4.625% at 100. +407bp vs 2.875% 08/15/28.

   - EUR400m due 07/15/28 (8y). NC3 (MWC B+50bp), then at 101.938, 100.969, 100. Equity claw: 3y 40% at 103.875. IPT 4.00%-4.25%. Px talk: 4% area. Launched: EUR400m at 3.875%. Priced: 3.875% at 100. +443bp vs DBR 0.25% 08/15/28.

USD550m upsize UOP: to redeem all its 9% sr sr notes. Did investor call at 2pm UKT, 9am NYT today. Books closed at 12pm NYT/5pm UKT today. Reconfirms were due at 1pm NYT/ 6pm UKT today. UOP: along with $140m cash on hand to redeem a portion (USD1.452bn) of its USD2bn 9% sr notes due 10/01/25 (MWC T+50bp). Also increasing and extending its revolver from $250m due Nov 2022 to $515m due July 2025. Biz: a global provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, HQ: Radnor, PA.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.